%0 Journal Article
%T Beneficios de la terapia con hidroxi¨²rea en ni£¿os con anemia de c¨¦lulas falciformes
%A Pe£¿a Siado
%A Jorge Enrique
%A V¨¦lez Villegas
%A Mar¨ªa Clara
%A S¨¢nchez Hern¨¢ndez
%A Diana Paola
%A Donado G¨®mez
%A Jorge Hernando
%J Iatreia
%D 2012
%I Universidad de Antioquia
%X objective: to assess the toxicity and benefits of hydroxyurea (hu) in the management of children with sickle cell disease (scd). materials and methods: a descriptive observationalretrospective study of patients with scd treated with hu was carried out at hospital pablo tob¨®n uribe in medellin, colombia, from may 2004 to september 2009. sixteen patients aged under 15 years were treated with this drug; out of them, 11 (68.8%) were male. all patients had sickle cell anemia (hb ss). the variables were studied before and after initiation of hu. results: average number of painful crises was 3.31 before and 1.13 after hu (p = 0.006); average number of red blood cell transfusions was 2.69 before and 0.75 after hu (p = 0.112); average number of acute chest syndrome episodes was 0.19 before and 0.13 after hu (p = 0.705); average number of hospitalizations was 1.94 before and 1.06 after hu (p = 0.155). one patient (6.3%) had hematologic toxicity, two patients (12.5%) had liver toxicity, and three patients (18.6%) had strokes. renal toxicity was not found. there were no malignancies. conclusion: hu significantly reduced the frequency of painful crises in our patients with scd. toxicity was generally acceptable. prospective multicenter, double-blind, placebo-controlled studies are required in order to define the role of hu in pediatric patients with scd.
%K hospitalization
%K hydroxyurea
%K sickle cell anemia
%K toxicity
%K transfusion.
%U http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0121-07932012000200002&lng=en&nrm=iso&tlng=en